Thank you to all fellows who joined us today in the
#ASCO24
@ASCOTECAG
lounge for a round table discussion on Navigating the Job Search, Interviews, & Contract Negotiations!
We published a comprehensive guide on this in
@ASCO
Connection in 2022 & hope you will find this helpful
Officially
@ABIMcert
board certified in Medical Oncology! Thanks to
@ABIMcert
โs longitudinal knowledge assessment, after 14+ years of proctored exams, I look forward to never having to walk into a testing center again! ๐๐ฅณ
Thank you kindly,
@ERPlimackMD
&
@myesmo
GU committee! Much more to learn about underpinnings of toxicity w/emergence of Tx w/novel MOAs & combos across GU cancers!
#ESMO23
๐๐ผ to my UNITE co-captains,
@koshkin85
&
@Tanjin097
, & all UNITE sites for your contributions & support!
Kudos to
@AmandaNizamMD
@ClevelandClinic
for winning ๐Best
#ESMO2023
Poster in Urothelial๐ Your original work pooling shared data across multiple institutions to seek tissue based and clinical biomarkers of toxicity to EV in
#bladdercancer
is even more relevant now that most M1
Thank you
@jamecancerdoc
,
@shilpaonc
, &
@CleClinicMD
for the opportunity to stay on and join our outstanding GU Onc team! Already excited to be back in clinic and look forward to building up our clinical and translational research collaborations with
@CCLRI
!
Few things in life can extricate me from Europe 4 days earlier than originally planned, but
#UromigosLive
is DEFINITELY one of them!!! Excited for this mtg on the heels of a successful & groundbreaking
#ESMO23
! ๐๐ผ๐๐ผ to
@Uromigos
for promoting junior faculty & for the opportunity!
@ClevelandClinic
Hematology/Oncology Fellowship Class of 2022. Last graduation after 14 years of education & training. Could not have asked for better co-fellows to grow with over the past 3 years. To continued success & meaning in our lifeโs work!
Off to
@ASCO
#GU23
! Looking forward to exciting science and trial updates, including a strong showing from our
@CleClinicMD
multidisciplinary GU Onc group!
Looking forward to seeing wonderful colleagues and friends!
Proud to be among the the highest-enrolling sites for this transformative trial in adv. bladder cancer! Gratitude for all of the pts who enrolled on EV-302 & all of the preceding trials over the years that helped us reach this point!
Thankful for
@shilpaonc
's leadership for
Thank you,
@ASCO
for naming me an Advocacy Champion in the Presidentโs Circle at the
#ASCOAdvocacySummit
. I am proud to advocate for:
โก๏ธ Action to mitigate drug shortages
โก๏ธ Continuation of telehealth flexibilities
โก๏ธ Robust research funding for the
@NIH
To get involved, visit
Thank you,
@ASCO
team, colleagues, & patient advocates for another successful
#ASCOAdvocacySummit
! And to the inimitable
@DGlaucomflecken
for an empowering keynote session!
Look forward to continuing to advocate locally & nationally over the next year!
See you all at
#ASCO24
!
Sending a big thank you to
@ASCOPres
& the exceptional
@ASCO
team! Our team tackled the Hill today, and this year's
#ASCOadvocacysummit
was our biggest one yet! There is still time for YOU to help! Click๐๐ป
Cruising over the Potomac into
@Reagan_Airport
will always be one of my favorite โ๏ธ landings.
Great to be back in the homeland!
Looking forward to seeing many old friends in DC and old and new friends at the
#ASCOAdvocacySummit
next week!
@ASCO
First
#BCANTT23
was wonderful! Many outstanding talks by passionate & brilliant colleagues in a rapidly evolving field. Most impressed by insightful & engaged pt advocates that were central to the meeting! ๐๐ผ
@BladderCancerUS
team for seamlessly dovetailing science & ptsโ voices!
That's a wrap! Thank you for an inspiring, informational, collegial and collaborative
#BCANTT23
. It's not too late to start thinking about
#BCANTT24
in San Diego August 7-9, 2024. Mark your calendars!
๐ฏ๐ฏ๐ฏ. I consistently use the
@FoxChaseCancer
ASSURE RCC Prognostic Nomogram when reviewing risk of recurrence & survival with pts in the post nephrectomy setting.
Adjuvant systemic Tx in select pts with resected high-risk RCC requires a careful discussion re: survival benefit
The ๐ slide from
@PBarataMD
discussion on the landscape of localized RCC post nephrectomy
Impt to incorporate risk calculators when discussing risk/benefit with patients
#GU24
@ASCO
We spoke with
@AmandaNizamMD
who provided an overview of her recent research on biomarkers of TRAEs associated with EV for advanced
#urothelialcarcinoma
, as well as results of the
#UNITE
study and some of its biggest takeaways. Watch now:
Such a pleasure to finally meet the brilliant and wonderful Dr.
@NicoleKuderer
in person after so many years! Look forward to learning so much from you! Thank you for supporting so many of us young investigators!
@gary_lyman
#ASCO23
#OncTwitter
Thanks,
@ASCO
ย for naming me an Advocacy Champion for my continued commitment to advocating for issues affecting the
#oncology
community.
-
#FixPriorAuth
& protect pt access to care
- Ensure copay assistance counts towards pt out-of-pocket costs
- Support fed. cancer research
The 2023
#ASCOAdvocacySummit
Week of Action starts todayโผ๏ธ Join us in urging Congress to:
-
#FixPriorAuth
& protect pt access to care
- Ensure copay assistance counts towards pt out-of-pocket costs
- Support federal cancer research
Take action โก๏ธ
Proud to support the incomparable
@DrChoueiri
for
@ASCO
BOD!
A legend in GU oncology. An unparalleled advocate, mentor, & sponsor for trainees/early career, IMGs, &
@ASCO
's IMG COP. The epitome of paying it forward!
Vote for this visionary leader to take
@ASCO
to new heights!!
Thank you,
@OncoAlert
,
@CParkMD
, &
@weoncologists
for the opportunity to discuss this poster from
#ASCO23
.
Congratulations to the
@VHIO
team for studying this important & clinically relevant question!
@crisuarez08
Would be very interesting to examine in pts treated with ADCs.
๐กOUTSTANDING
#ASCO23
@OncoAlert
update on โEffect on outcomes of toxicity-related dose reduction in TKI monotherapy or TKI-IO combination therapy for adv. renal cell carcinomaโ, by rising GU superstar Dr. Amanda Nizam
@AmandaNizamMD
.
@weoncologists
๐
EV-302 Subgroup Analyses presented by
@MichvdHeijden
#GU24
#blcsm
@ASCO
๐ท EV+P improved PFS & OS regardless of cisplatin-eligibility and PD-L1 expression
๐ทEV+P improved PFS & OS regardless of presence of liver, visceral, or LN metastases
๐ท EV+P improved PFS and OS across all
This ๐ฏ๐ฏ๐ฏ! How fortunate we are to have so many brilliant & hard-working ๐immigrants in medicine! So many examples in GU Oncology alone who have pushed their fields forward. Kudos to those who pay it forward by sponsoring & investing in these dedicated & talented physicians!
Beautifully said. I always think of this in the context of
@NazliDizman
, coming here from
#Turkey
s/p extensive training, doing 3y of rsrch at
@cityofhope
, then 3y more at
@Yale
for
#residency
. Couldn't have been EZ, but ๐at the productivity as she gears up for
#fellowship
apps!
FELIZ CUMPLEAรOS a mi amiga & fellow Scorpio โ๏ธ,
@AnaVManana
!! ๐ฅณ๐ฅณ A brilliant oncologist, researcher, servant leader, mentor, advocate, and role model for myself and so many others! Eternally grateful for your friendship!!! ๐ฅฐ
@NazliDizman
Advocacy is a critical pillar of our roles as physicians. Thank you to
@ASCO
for facilitating local & national advocacy efforts to drive meaningful change for our patients with cancer.
Proud of my fellow
@ASCOTECAG
& GU Oncology colleagues & friends who consistently advocate
Excited to share our trainee experiences during the COVID-19 pandemic!
Congrats to all of my ๐ co-authors! It was a delight to collaborate on this! Special ๐๐ผ to
@RahulBanerjeeMD
for shepherding this from start to finish!
Many ๐๐ผ
@NicoleKuderer
&
@gary_lyman
for your support!
1/ Super proud of my co-authors!
When future generations ask why our research directions suddenly changed and our protocols dramatically under-accrued as fellows from 2020-2023, we'll point to this ๐
(Not all gloom & doom: silver linings covered too!)
#ESMO3
2394P: Biomarkers of EV TRAEs in aUC pts on EV mono
๐UNITE (16 US sites) โก๏ธ 275 pts w/EV TRAEs & NGS
๐นMVA: poss. assoc. btwn MLL2 alt/cytopenias & KDM6A alt/anorexia + wt. โฌ๏ธ
โOverall, somatic alt status doesnโt appear to be a/w EV TRAE
๐Addโl MVAs w/clin. biomarkers
๐ข
#OncTwitter
:
Vote for Dr.
@montypal
for
@ASCO
Nominating Committee โ Undesignated Member! An exceptional oncologist & human being whose inimitable vision, leadership, & commitment to trainees/junior faculty will take
@ASCO
to new heights!
#VoteMonty
Thank you,
@shilpaonc
,
@MosheOrnsteinMD
, Dr. Diaz-Montero, &
@CCLRI
for your mentorship and support on this project! Excited to stay on at
@ClevelandClinic
to start my career in GU Oncology and look forward to prospectively studying immune-related toxicity across GU cancers!!
Great news with tumor agnostic approval for pts with Tx-refractory HER2+ (IHC3+) cancers, including bladder Ca!
With other HER2-directed ADCs on the horizon (e.g., DV, T-DM1), key issue will be standardization of HER2 testing in bladder Ca.
@koshkin85
@Dr_Aggen
@JasonBrownMDPhD
T-DXd is approved for the treatment of patients with ANY treatment-refractory HER2+ (IHC 3+) tumor, making of it the first agnostic ADC. Unlikely to be the last. Key priority: ensuring that HER2 testing is expanded across cancer types. Exciting times!
Dr. Shilpa Gupta discusses "Optimizing survival for patients with muscle invasive bladder cancer," from the big stage at
@ASCO
#GU23
@shilpaonc
A great review of the current multi-disciplinary SOC as well as emerging therapies for MIBC.
@CleClinicMD
@ClevelandClinic
Delighted to land in the โexperimental armโ for what is sure to be a successful & invigorating inaugural
@Uromigos
Unplugged in
#Nashville
! Looking forward to learning from the brightest minds in GU on the heels of
#ESMO22
.๐๐ผ to
@brian_rini
,
@tompowles1
, & organizers for the opp!
We have a 2nd golden ticket award winner โฆ
@AmandaNizamMD
โฉ for Nashvilleโ22 . Amanda highlights ongoing uncertainty around the agenda and faculty. โฆโฆ
@brian_rini
โฉ assures us the social events are maturing well.
๐ Join us in congratulating Dr. Nizar Tannir
@MDAndersonNews
, who will receive the Nicholas J. Vogelzang Humanitarian Award at
#IKCSNA23
. His service, mentorship, & advocacy for the
#kidneycancer
community is unparalleled ๐งก
Read the Press Release:
More stellar ๐ from UNITE on indep. biomarkers assoc. w/EV outcomes & biomarkers of SG response & efficacy of SG post-EV! Outstanding job by ๐คฉ future Dr.
@Tanjin097
, who is applying to med school this year!
Exceptional & incomparable mentor
@koshkin85
here in spirit! ๐
#ASCO23
We found an independent association btwn several molecular biomarkers & EV outcomes in pts with aUC:
๐ข ERBB2 alterations: โฌ๏ธ OS
๐ข KDM6A alterations: โฌ๏ธ OS
๐ด PIK3CA alterations: โฌ๏ธ ORR
๐ด High PD-L1 expression: โฌ๏ธ OS & โฌ๏ธORR
๐ด Low TMB: โฌ๏ธ OS
See poster๐๐ผ
#ASCO2023
1/2
THIS is the definition of tenacity!
Congratulations to the brilliant
@LauraBukavinaMD
& her team for continuing to lead the way in gut microbiome research in bladder cancer!
Much more to learn about the role of the gut microbiome in cancer pathogenesis & anti-tumor response as
๐ฏ๐ฏ๐ฏ Thank you,
@ASCO
staff, for your tireless commitment to the oncology community & our patients with cancer! A successful and empowering
#ASCOAdvocacySummit
which was seamless thanks to you all!
#OncTwitter
THANK YOU,
@ASCO
staff! Incredibly grateful and thankful for your meticulous attention to every detail at
#ASCOAdvocacySummit
, for taking such great care of us all, and for empowering each of us to be ambassadors for our patients and peers!
๐ธ of our staff rockstars in action!
Thank you,
@CParkMD
for your infectious optimism, collaborative spirit, & for being a truly generous sponsor for many of us junior investigators!
You truly pay it forward by connecting, educating, & mentoring so many in the oncology world! Proud to be your friend!!
#ASCO24
โฌ๏ธ The outstanding national leadership for healthcare + cancer care in the USA ๐บ๐ธ. What an inspiring day + proud moment for
#WomeninMedicine
#WomeninSTEM
. โฆ
@NIH
โฉ โฆ
@theNCI
โฉ
Thank you for attending & for all of your insightful questions! We were very happy to chat with residents, med students, and high school students! The future is bright!
@ASCOTECAG
#ASCO24
Congrats to my sister friend,
@ZeynepZengin
, and
@LuisMezaco
for matching at their
#1
program! You will do great!! ๐ฅณ๐ฅณ๐ Congratulations also to
@montypal
for outstanding mentorship and a legacy of nurturing brilliant and talented IMGs!
#MatchDay
Congratulations to Prof.
@tompowles1
, Dr.
@brian_rini
, & the entire Mashup Media team for an extraordinarily successful & invigorating inaugural
#UromigosLive
! An unparalleled format with brilliant panelists! Very grateful to attend as one of the golden ๐ winners!
@GUOncologyNow
This๐๐ผ. Always insightful and meaningful contributions from Dr.
@AnaVManana
to address inequities in health care. A true role model in โwalking the walkโ through her passionate work and advocacy! Proud of my admirable friend!
#ASCO23
โผ๏ธโด๏ธ Ready or not here we go! Day 2
#GU24
for
#urothelial
carcinoma! โผ๏ธ
Excitedly waiting for rockstar
@AmandaNizamMD
โs stellar oral talk!
Well said from one of Dr.
@montypal
โs ๐ mentees, Dr.
@NazliDizman
. Always paying it forward, his inimitable vision, leadership, & talent will catalyze ASCOโs growth & impact in the years to come! ๐๐ผ for your dedication to
@ASCO
& esp. the next gen of investigators!
#VoteMonty
๐Thrilled to support
@montypal
for the nominating committee position in the
@ASCO
elections!
An outstanding physician/researcher/advocate, amazing mentor & visionary leader committed to serving patients &
@ASCO
๐
๐ Voting opens on 11/2
#VoteMonty
#VoteASCO
#OncTwitter
Outstanding presentation from๐๐
@Tanjin097
on biomarkers of response to EV from the UNITE study! Med schools - watch out for this ๐ applicant this year!
๐๐ผ to the UNITE team led by ๐ mentor,
@koshkin85
! Thanks for including us @ CCF! More to come from this great collab!
#gu23
Analysis of retrospective UNITE study data shows โฌ๏ธPFS with CDKN2A/B and MTAP alterations and โฌ๏ธ OS with high TMB. โฌ๏ธ ORR with TSC1 and ERBB2 alterations. Great work Tanya Jindal!
@koshkin85
. Looking forward to getting this study open at
@UHhospitals
No
@ASCO
conference is complete w/o an outstanding showing from
#TeamPal
! Incredibly impressed by all of the presentations from undergraduates at
#GU23
! The future of oncology is bright! ๐๐ผ to the many amazing mentors in our field! Special ๐๐ผ to
@arafflemd
for 4 takes of ๐ธ
#1
๐
What an exciting time for patients, advocates, & providers in GU oncology! The power of science, collaboration, & persistence to get these trials over the finish line! Looking forward to attending my first
@myESMO
#ESMO23
& presenting our work on EV TRAEs!
@koshkin85
@Tanjin097
๐๐ผ to
@AnaVManana
for her outstanding leadership of the
@ASCO
TECAG! Itโs been so fun working w/colleagues &
@ASCO
staff! I look forward to continuing to serve on TECAG under the leadership of the brilliant
@ramsedhom
! Stay tuned for more from all of us at
#ASCO22
& this summer!
Excited to welcome & pass the baton to
@ramsedhom
as new Chair of
#ASCOTrainee
council 2022-2023 ๐
Itโs been an amazing year working w/ colleagues to promote
#oncology
education & trainee career development
Looking forward to seeing you all at
#ASCO22
& welcome our new members!
Midterms may be over, but ASCO elections are still going on!
Donโt forget to vote for a truly inspiring & visionary leader, Dr.
@montypal
, for
@ASCO
Nominating Committee - Undesignated Member! The future of oncology &
@ASCO
is bright!๐
@AnaVManana
@NazliDizman
@crisbergerot
๐ข
#OncTwitter
:
Vote for Dr.
@montypal
for
@ASCO
Nominating Committee โ Undesignated Member! An exceptional oncologist & human being whose inimitable vision, leadership, & commitment to trainees/junior faculty will take
@ASCO
to new heights!
#VoteMonty
So proud of our rockstar
@CleClinicMD
fellow
@DimaDanai
for a stellar presentation on real world teclistamab in
#mmsm
. Similar responses to clinical trial although many of our patients would have been ineligible!
Truly impressed by the interest generated by our review on optimizing the safety of ADCs, ranked 1st among articles of the same age on
@NatRevClinOncol
!
โณ๏ธ You can now use this link to read the article without paywall ๐
๐๐ผ,
@PGrivasMDPhD
, & to the Leo & Anne Albert Institute for the opportunity to discuss how to optimally sequence systemic Tx in mUC in a very dynamic landscape! Looking forward to EV302 & CM901 data! ๐๐ผ to
@JasonBrownMDPhD
@Tanjin097
@OAlhalabiMD
@NazliDizman
for help practicing!
What an invigorating
#GU22
! Nothing more inspiring than reuniting in person to witness the myriad of ways our brilliant colleagues continue to push the field forward in the multi-disciplinary care of pts with GU cancers. 1/4
#GU22
ended with a beautiful sunset! Thanks to the faculty, committee members, staff, vendors and attendees that made it great. Looking forward to seeing you all again June 3-7 in Chicago for
#ASCO22
. Learn more at
Thank you to the entire
@ASCO
community - especially staff, volunteers, and organizers - for a wonderful
#ASCO22
meeting! It was such a joy to reunite in person for the first time in 3 years! Until the next conference! Safe travels to all!
I find myself at a loss for words as the meeting ends but I am so thankful for the amazing community of ASCO staff, vendors, faculty and volunteers that made
#ASCO22
possible. Watching the ASCO community reunite was a joy. Looking forward to seeing you all again at
#ASCO23
Much gratitude to super mentor & collaborator,
@koshkin85
, brilliant & creative UNITE co-pilot
@Tanjin097
, & all UNITE collaborators! Grateful to be a part of
#UNITE
and look forward to ongoing & future UNITE studies to help answer difficult โin a rapidly evolving Tx landscape
Incredibly important personalized
#PCa
screening recommendations for Black men from Dr.
#IslaGarraway
@dgsomucla
&
@PCFnews
@ASCO
#GU24
๐ Abs. 264 / Poster K21
๐ท Poster Session A: PCa
๐ Thurs. 1/25/2024
โฑ๏ธ 11:30am - 1:00pm PST
๐Level 1, West Hall
I remember being so impressed by
@AJangMD
โs proactiveness & curiosity at
#GU22
! Continue to be impressed to this day! Have so enjoyed watching this rising โญ๏ธ & genuinely kind human continue to soar with his excellent work under the outstanding mentorship of
@PBarataMD
!
#GU24
Congratulations to ๐
#UNITE
co-pilot
@Tanjin097
on winning Best Poster at
#ESMOTAT24
!! Important work from
#UNITE
examining characteristics of pts with aUC with primary resistance to EV.
Need to understand biological mechanisms differentiating pts with CR vs. PD to frontline
In UNITE, we saw patients with aUC who experienced primary PD on EV, had more CDKN2B alterations and were more likely to receive platinum-based chemo as tx immediately prior to EV compared to those without primary PD
#ESMOTAT
@koshkin85
@PGrivasMDPhD
@AmandaNizamMD
@urotoday
๐๐ผ
@kaydaustin
, & all pt advocates for embracing your powerful voices! We learn from & are driven by our pts in our clinical & research efforts. It is our prerogative as physicians to embrace our role as advocates in partnership WITH our pts. We cannot drive progress alone.
@ASCO
What's it like being a once shy and very introverted patient advocate at the largest oncology conference?
A thread on
#ASCO23
from a patient perspective and a heartfelt thank you to those who truly embodied ASCO's theme this year - Partnering with Patients ๐
Very proud of colleagues spearheading this effort!
@ASCO
#ASCOAdvocacy
has been a staunch advocate for removing barriers to telehealth coverage.
Ask your lawmakers to support:
๐S.2016/H.R.4189: CONNECT for Health Act of 2023
1/n Today we've started a legal campaign to break down state telehealth licensure restrictions. The fact that MD specialists, already licensed in their home state, must also obtain full licensure in every state where their potential patients reside violates the US Constitution๐งต
Check out our editorial on CV risk in men with prostate cancer treated with ADT
@pcan_journal
We discuss the need to develop risk models specific to men with PCa and to better understand the biologic determinants of toxicity
@aaparicioMD
@MDAndersonNews
Congratulations to the incomparable rockstar,
#RMS
!!! ๐คฉ๐คฉ๐คฉ So proud of you and so well deserved! What a GU powerhouse at Yale!!
@DrChoueiri
@BraunMDPhD
โญ๏ธOver the moon to have matched at
@YaleIMed
I cannot wait to experience and hopefully live up to:
"As good as any, nicer than most"
@MarkDSiegel1
(I can finally use this GIF! hope I do better than Rory!)
Outstanding presentation, as always, by the
#PCa
master,
@neerajaiims
!
Important context for CONTACT-2 findings: Cabo-atezo vs. 2nd NHT was studied in a highly selected population of pts with measurable extrapelvic soft tissue metastasis.
#GU24
@DrYukselUrun
@TiansterZhang
Very comprehensive & well-written review on an important & often understudied topic. Will become even more important to study with the rapid development of novel therapeutics & Tx combinations. Congratulations to the authors!
@NicoleKuderer
@ADesaiMD
@maryam_lustberg
@gary_lyman
โญ๏ธ The burden of chemotherapy-toxicity remains high & is associated with considerable morbidity, mortality and costs. Comprehensive review on management of acute chemotherapy related toxicities in patients with cancer
@NatRevClinOncol
This is so terribly sad ๐ฅบ. Had the pleasure of sitting w/
@bodagetta
& his now hubby
@Uromigos
Live 2022 & have loved following him on Twitter since. What a remarkable advocate for pts w/RCC. ๐๐ผ for sharing your journey & helping so many w/your kindness & humor. Weโll miss youโฆ
Heartbroken by the news of Michaelโs passing. Michael, you will be deeply missed and Iโll think of you and your waiting room floor series as I sit in every waiting room lobby, silently judging the patterns on the flooring. I hate this disease ๐ข๐งก Going to miss you friend
Thank you to all who have helped shape us - countless mentors near & far, our awesome PD, Dr. McNamara, & APDs, Dr.
@MeganKruseMD
, Dr. Shapiro, & Dr. Mazzoni. Look forward to starting the next chapter at
@CleClinicMD
with our outstanding GU Oncology group under
@shilpaonc
โs helm!
Tune in to this timely & informative session led by
@shilpaonc
&
@DrJohnSfakianos
! See โฌ๏ธ.
With approval of EV/pembro in aUC, adjuvant nivo, & ongoing perioperative trials investigating IO-based regimens,โre: IO sequencing, rechallenge, & pairing will arise frequently.
#GU24
Always knew
@thenasheffect
had some secret superpower!!
#visaninja
๐ฆน๐ปโโ๏ธ What a testament to your tenacity & dedication to academia!
Even more commendable is his commitment to paying it forward with his mentorship & collaboration with other exceptional IMGs!
@TalalZarif1
I have been on every visaโฆF1, J-1 alien ๐ truly inspiring journey of an amazingly successful young academic oncologist โฆ
@thenasheffect
โฉ !! So proud of you !! โฆ
@IMG_Oncologists
โฉ โฆ
@ASCO
โฉ
#ASCO24
We are very proud of this year's
#TECLounge
with all the new amenities and superb educational sessions. We had great time learning, having fun and connecting with friends. Thank you
@ASCO
,
@asco
staff and
@FernandoDiazMD1
for the recognition and all the hard work.
@ASCOTECAG
Excellent & timely Keynote from
@ctleeuro
:
๐ท Need to enrich for pt populations in trials w/similar or โฌ๏ธ mortality compared to ref. White pop.
๐ท Diverse population of US allows unique opportunity for US sites to โฌ๏ธ diversity in global clinical trials
๐ท
@WalterStadler5
:
The MAINCAV randomised trial explores the addition of cabozantinib to avelumab as 1st line maintenance therapy in advanced bladder cancer. 650 patients required to show and OS advantage (primary endpoint). Congrats to Shilpa and the team.
@shilpaonc
Thanks to the amazing
@ASCO
team & all staff for another spectacular
#GU24
!! We couldnโt do what we do without you! Safe travels to all & look forward to seeing you at
#ASCO24
!! ๐
That's a wrap
#GU24
! 20 years! Wild to think I've been w
@ASCO
for the majority of them (obvi started working at 5yo ๐ซฃ๐คฃ). It's an honor to support the brightest minds in cancer research. It's even sweeter when they become friends. Never feels like work when you're w friends ๐ซถ
Anyone interested in
#HRQOL
&
#toxicity
should be following
@crisbergerot
โs consistently outstanding work! Focusing on what is important & matters most to pts.
Kudos also to
@RCCadvocate
for studying pt preferences in RCC & calling our attention to this!
We must incorporate